Vanguard Group
CRBP icon

Vanguard Group’s Corbus Pharmaceuticals CRBP Stock Holding History

Vanguard Group’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$7M Buy
859,407
+247,377
+40% +$3.05M ﹤0.01% 3126
2025
Q3 		$7.74M Buy
612,030
+12,535
+2% +$119K ﹤0.01% 3115
2025
Q2 		$4.14M Sell
599,495
-72,562
-11% -$527K ﹤0.01% 3273
2025
Q1 		$3.57M Buy
672,057
+12,855
+2% +$113K ﹤0.01% 3292
2024
Q4 		$7.78M Buy
659,202
+13,552
+2% +$227K ﹤0.01% 3075
2024
Q3 		$13.3M Buy
645,650
+60,661
+10% +$3.1M ﹤0.01% 2812
2024
Q2 		$26.5M Buy
584,989
+147,725
+34% +$6.21M ﹤0.01% 2433
2024
Q1 		$17.2M Buy
437,264
+257,808
+144% +$6.36M ﹤0.01% 2677
2023
Q4 		$1.08M Hold
179,456
– – ﹤0.01% 3799
2023
Q3 		$1.21M Hold
179,456
– – ﹤0.01% 3763
2023
Q2 		$1.41M Buy
179,456
+1
+0% +$9 ﹤0.01% 3789
2023
Q1 		$1.3M Buy
179,455
+44,485
+33% +$195K ﹤0.01% 3833
2022
Q4 		$447K Buy
134,970
+78
+0.1% +$300 ﹤0.01% 4123
2022
Q3 		$668K Sell
134,892
-8,180
-6% -$57.7K ﹤0.01% 4134
2022
Q2 		$1.08M Hold
143,072
– – ﹤0.01% 4062
2022
Q1 		$2.28M Sell
143,072
-37,070
-21% -$491K ﹤0.01% 3903
2021
Q4 		$3.33M Sell
180,142
-2,086
-1% -$56.5K ﹤0.01% 3827
2021
Q3 		$5.58M Buy
182,228
+160
+0.1% +$6.31K ﹤0.01% 3588
2021
Q2 		$10M Buy
182,068
+55,275
+44% +$3.07M ﹤0.01% 3201
2021
Q1 		$7.49M Buy
126,793
+3,065
+2% +$201K ﹤0.01% 3318
2020
Q4 		$4.64M Sell
123,728
-13,668
-10% -$511K ﹤0.01% 3393
2020
Q3 		$7.42M Buy
137,396
+18,389
+15% +$3.33M ﹤0.01% 2946
2020
Q2 		$30M Buy
119,007
+504
+0.4% +$102K ﹤0.01% 2238
2020
Q1 		$18.6M Buy
118,503
+11,133
+10% +$1.88M ﹤0.01% 2322
2019
Q4 		$17.6M Buy
107,370
+2,660
+3% +$393K ﹤0.01% 2592
2019
Q3 		$15.3M Buy
104,710
+2,038
+2% +$355K ﹤0.01% 2602
2019
Q2 		$21.3M Buy
102,672
+7,354
+8% +$1.57M ﹤0.01% 2480
2019
Q1 		$19.9M Buy
95,318
+12,924
+16% +$2.85M ﹤0.01% 2508
2018
Q4 		$14.4M Buy
82,394
+2,727
+3% +$544K ﹤0.01% 2594
2018
Q3 		$18M Buy
79,667
+387
+0.5% +$62.6K ﹤0.01% 2627
2018
Q2 		$12M Buy
79,280
+7,236
+10% +$1.31M ﹤0.01% 2810
2018
Q1 		$13.2M Buy
72,044
+639
+0.9% +$144K ﹤0.01% 2680
2017
Q4 		$15.2M Buy
71,405
+13,958
+24% +$2.99M ﹤0.01% 2618
2017
Q3 		$12.3M Buy
57,447
+5,333
+10% +$1.04M ﹤0.01% 2711
2017
Q2 		$9.85M Buy
52,114
+10,266
+25% +$2.01M ﹤0.01% 2780
2017
Q1 		$10.4M Buy
41,848
+2,381
+6% +$584K ﹤0.01% 2751
2016
Q4 		$10M Sell
39,467
-217
-0.5% -$49.7K ﹤0.01% 2743
2016
Q3 		$8.08M Buy
39,684
+17,854
+82% +$2.22M ﹤0.01% 2791
2016
Q2 		$1.96M Buy
21,830
+5,644
+35% +$443K ﹤0.01% 3393
2016
Q1 		$879K Buy
16,186
+1,481
+10% +$65.3K ﹤0.01% 3633
2015
Q4 		$728K Buy
14,705
+547
+4% +$27.9K ﹤0.01% 3722
2015
Q3 		$667K Buy
14,158
+3,034
+27% +$202K ﹤0.01% 3759
2015
Q2 		$1.03M Buy
+11,124
New +$1.12M ﹤0.01% 3656

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Vanguard Group's CRBP Position: Q4 2025 in Review

Vanguard Group increased its Corbus Pharmaceuticals (CRBP) stake by 40% in Q4 2025, buying an estimated $3.05M and bringing the position to 859,407 shares worth $7M. The position accounts for ﹤0.01% of the portfolio, ranked #3126.

Vanguard Group first reported a position in CRBP in Q2 2015 and has held it in 43 quarters since. The position peaked at $30M in Q2 2020. 100 funds tracked by Wall St. Rank hold CRBP as of Q4 2025.

  • Vanguard Group held 859,407 shares of Corbus Pharmaceuticals worth $7M as of Q4 2025.
  • Vanguard Group bought 247,377 Corbus Pharmaceuticals shares in Q4 2025, an estimated $3.05M.
  • Corbus Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3126 holding.
  • Vanguard Group first reported a position in Corbus Pharmaceuticals in Q2 2015 and has held it in 43 quarters since.
  • Vanguard Group's Corbus Pharmaceuticals position peaked at $30M in Q2 2020.
  • 100 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.